A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer

Sakamoto,Tomohiro; Kodani,Masahiro; Takata,Miyako; Chikumi,Hiroki; Nakamoto,Masaki; Nishii-Ito,Shizuka; Ueda,Yasuto; Izumi,Hiroki; Makino,Haruhiko; Touge,Hirokazu; Takeda,Kenichi; Yamasaki,Akira; Yanai,Masaaki; Tanaka,Natsumi; Igishi,Tadashi; Shimizu,Eiji

doi:10.3892/ijo.2015.2875

A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer

Authors:
- Tomohiro Sakamoto
- Masahiro Kodani
- Miyako Takata
- Hiroki Chikumi
- Masaki Nakamoto
- Shizuka Nishii-Ito
- Yasuto Ueda
- Hiroki Izumi
- Haruhiko Makino
- Hirokazu Touge
- Kenichi Takeda
- Akira Yamasaki
- Masaaki Yanai
- Natsumi Tanaka
- Tadashi Igishi
- Eiji Shimizu
View Affiliations

Affiliations: Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University, Yonago, Japan
Published online on: February 4, 2015 https://doi.org/10.3892/ijo.2015.2875
Pages: 1473-1480
Copyright: © Sakamoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidermal growth factor receptor (EGFR) gene mutation testing is essential for choosing appropriate treatment options in patients with advanced non-small cell lung cancer (NSCLC). However, a time delay occurs between histological diagnosis and molecular diagnosis in clinical situations. To minimize this delay, we developed a novel point-of-care test for EGFR mutations, based on a high-speed real-time polymerase chain reaction (PCR) system designated here as ultrarapid PCR combined with highly accurate bronchoscopic sampling. We investigated whether our system for detecting EGFR mutations was valid by comparing test results with those obtained using a commercialized EGFR mutation test. We obtained small amounts of bronchial lavage fluids after transbronchial biopsies (TBBs) were performed on enrolled patients (n=168) who underwent endobronchial ultrasonography using a guide sheath (EBUS-GS). EGFR mutation analysis was performed by ultrarapid PCR immediately after EBUS-GS-TBBs were obtained (on the same day). After pathological diagnoses of NSCLC, EGFR mutation status in formalin-fixed, paraffin- embedded samples was confirmed by the PCR-invader method, and the concordance rates between the PCR methods were compared. The total diagnostic yield of EBUS-GS-TBB was 91.0%. The positive concordance rates for detecting 19del and L858R with the ultrarapid PCR and PCR-invader methods were both 100%. Negative concordance rates were 97.2 and 98.1%, respectively. We also demonstrated a dramatic effect of early erlotinib administration, based on ultrarapid PCR results, for a 52-year-old woman suffering from respiratory failure due to severe intrapulmonary metastases with poor performance status. In conclusion, ultrarapid PCR combined with EBUS-GS-TBB enabled rapid and reliable point-of-care testing for EGFR mutations.

View Figures

View References

1	Fukuoka M, Wu YL, Thongprasert S, et al: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar : PubMed/NCBI
2	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
3	Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
4	Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
5	Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
6	Asano H, Toyooka S, Tokumo M, et al: Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res. 12:43–48. 2006. View Article : Google Scholar : PubMed/NCBI
7	Hoshi K, Takakura H, Mitani Y, et al: Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin Cancer Res. 13:4974–4983. 2007. View Article : Google Scholar : PubMed/NCBI
8	Hall JG, Eis PS, Law SM, et al: Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction. Proc Natl Acad Sci USA. 97:8272–8277. 2000. View Article : Google Scholar : PubMed/NCBI
9	Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 65:7276–7282. 2005. View Article : Google Scholar : PubMed/NCBI
10	Naoki K, Soejima K, Okamoto H, et al: The PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. Int J Clin Oncol. 16:335–344. 2011. View Article : Google Scholar : PubMed/NCBI
11	Sasaki H, Endo K, Konishi A, et al: EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res. 11:2924–2929. 2005. View Article : Google Scholar : PubMed/NCBI
12	Fujimoto T, Konagaya M, Enomoto M, et al: Novel high-speed real-time PCR method (Hyper-PCR): results from its application to adenovirus diagnosis. Jpn J infect Dis. 63:31–35. 2010.PubMed/NCBI
13	Asahina H, Yamazaki K, Onodera Y, Kikuchi E, Shinagawa N, Asano F and Nishimura M: Transbronchial biopsy using endobronchial ultrasonography with a guide sheath and virtual bronchoscopic navigation. Chest. 128:1761–1765. 2005. View Article : Google Scholar : PubMed/NCBI
14	Asano F, Matsuno Y, Shinagawa N, Yamazaki K, Suzuki T, Ishida T and Moriya H: A virtual bronchoscopic navigation system for pulmonary peripheral lesions. Chest. 130:559–566. 2006. View Article : Google Scholar : PubMed/NCBI
15	Eberhardt R, Anantham D, Ernst A, Feller-Kopman D and Herth F: Multimodality bronchoscopic diagnosis of peripheral lung lesions: a randomized controlled trial. Am J Respir Crit Care Med. 176:36–41. 2007. View Article : Google Scholar : PubMed/NCBI
16	Eberhardt R, Kahn N, Gompelmann D, Schumann M, Heussel CP and Herth FJ: LungPoint - a new approach to peripheral lesions. J Thorac Oncol. 5:1559–1563. 2010. View Article : Google Scholar : PubMed/NCBI
17	Fielding DI, Chia C, Nguyen P, Bashirzadeh F, Hundloe J, Brown IG and Steinke K: Prospective randomised trial of endobronchial ultrasound-guide sheath versus computed tomography-guided percutaneous core biopsies for peripheral lung lesions. Intern Med J. 42:894–900. 2012. View Article : Google Scholar : PubMed/NCBI
18	Gildea TR, Mazzone PJ, Karnak D, Meziane M and Mehta AC: Electromagnetic navigation diagnostic bronchoscopy: a prospective study. Am J Respir Crit Care Med. 174:982–989. 2006. View Article : Google Scholar : PubMed/NCBI
19	Seijo LM, de Torres JP, Lozano MD, Bastarrika G, Alcaide AB, Lacunza MM and Zulueta JJ: Diagnostic yield of electromagnetic navigation bronchoscopy is highly dependent on the presence of a Bronchus sign on CT imaging: results from a prospective study. Chest. 138:1316–1321. 2010. View Article : Google Scholar : PubMed/NCBI
20	Kurimoto N, Miyazawa T, Okimasa S, Maeda A, Oiwa H, Miyazu Y and Murayama M: Endobronchial ultrasonography using a guide sheath increases the ability to diagnose peripheral pulmonary lesions endoscopically. Chest. 126:959–965. 2004. View Article : Google Scholar : PubMed/NCBI
21	Kundel HL and Polansky M: Measurement of observer agreement. Radiology. 228:303–308. 2003. View Article : Google Scholar : PubMed/NCBI
22	Landis JR and Koch GG: The measurement of observer agreement for categorical data. Biometrics. 33:159–174. 1977. View Article : Google Scholar : PubMed/NCBI
23	Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E and Peters S; ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24(Suppl 6): vi89–vi98. 2013. View Article : Google Scholar : PubMed/NCBI
24	Ishida T, Asano F, Yamazaki K, et al: Virtual bronchoscopic navigation combined with endobronchial ultrasound to diagnose small peripheral pulmonary lesions: a randamized trial. Thorax. 66:1072–1077. 2011. View Article : Google Scholar : PubMed/NCBI
25	Yamaguchi F, Kugawa S, Tateno H, Kokubu F and Fukuchi K: Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. Lung Cancer. 78:201–206. 2012. View Article : Google Scholar : PubMed/NCBI
26	Jurado J, Saqi A, Maxfield R, et al: The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma. Ann Thorac Surg. 96:1196–1202. 2013. View Article : Google Scholar : PubMed/NCBI
27	Santis G, Angell R, Nickless G, Quinn A, Herbert A, Cane P, Spicer J, Breen R, McLean E and Tobal K: Screening for EGFR and KRAS mutations in endobronchial ultrasound derived trans-bronchial needle aspirates in non-small cell lung cancer using COLD-PCR. PLoS One. 6:e251912011. View Article : Google Scholar
28	Tsai TH, Yang CY, Ho CC, et al: Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. Lung Cancer. 82:420–425. 2013. View Article : Google Scholar : PubMed/NCBI
29	Lewandowska MA, Jozwicki W, Jochymski C and Kowalewski J: Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients. Oncol Rep. 30:1045–1052. 2013.PubMed/NCBI
30	van Eijk R, Licht J, Schrumpf M, et al: Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One. 6:e177912011. View Article : Google Scholar : PubMed/NCBI
31	Buttitta F, Felicioni L, Del Grammastro M, et al: Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res. 19:691–698. 2013. View Article : Google Scholar
32	Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 22:330–353. 2004. View Article : Google Scholar
33	Inoue A, Kobayashi K, Usui K, et al: First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 27:1394–1400. 2009. View Article : Google Scholar : PubMed/NCBI
34	Kudoh S, Kato H, Nishiwaki Y, et al: Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI
35	Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824. 2007. View Article : Google Scholar : PubMed/NCBI
36	Watanabe S, Minegishi Y, Yoshizawa H, et al: Effectiveness of gefitinib against non-small-cell lung cancer with uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 9:189–194. 2014. View Article : Google Scholar : PubMed/NCBI
37	Cross DA, Ashton SE, Ghiorghiu S, et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Dicov. 4:1046–1061. 2014. View Article : Google Scholar